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Abstract The phase III, multicenter, randomized, pla-
cebo-controlled PreCISe trial assessed glatiramer acetate
(GA) effects in patients with clinically isolated syndromes
(CIS) suggestive of multiple sclerosis (MS). To assess the
neuroprotective effect of GA in a subset of patients in the
PreCISe trial, we used proton magnetic resonance spec-
troscopy (MRS) to measure N-acetylaspartate (NAA), a
marker of neuronal integrity, in a large central volume of
brain. Thirty-four CIS patients randomized to GA 20 mg/
day (n = 19) SC or placebo (n = 15) were included.
Patients who relapsed (developed clinically definite MS
[CDMS]) were removed from the substudy. NAA/creatine
(NAA/Cr) ratios were compared between GA-treated and
placebo-treated patients. Twenty patients with CIS had not
converted to CDMS and were still in the double-blind
phase of the trial at 12 months of follow-up. Paired chan-
ges in NAA/Cr differed significantly in patients treated
with GA (?0.14, n = 11) compared with patients receiving
placebo (-0.33, n = 9, p = 0.03) at 12 months, consistent
with a neuroprotective effect of GA in vivo. Patients with
CIS who received GA showed improvement in brain neu-
roaxonal integrity, as indicated by increased NAA/Cr,
relative to comparable patients treated with placebo, who
showed a decline in NAA/Cr consistent with findings from
natural history studies.
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Introduction
The importance of neuroaxonal degeneration as the sub-
strate of chronic irreversible disability in multiple sclerosis
(MS) is being increasingly appreciated [1]. The neurological
impairment that occurs with MS relapses results primarily
from acute conduction block associated with demyelination
and inflammation [2]. Resolution of inflammation, along
with remyelination of axons that are not transected, and
insertion of new sodium channels to allow conduction
across segments of axons that remain demyelinated, can
lead to reversal of the disability attributable to these factors.
However, axons are often transected in acute lesions, and
axons that are not transected but remain demyelinated may
degenerate due to increased influx of sodium and calcium,
loss of trophic support by myelin, and impaired axonal
transport and mitochondrial function. Irreversible injury and
loss of axons lead to an irreversible loss of nervous system
function and, to the extent that cerebral plasticity and
redundancy cannot compensate, to irreversible functional
impairment and disability. Chronic diffuse inflammation
within the CNS [3] probably accelerates the loss of axons.
The integrity of axons in MS can be assessed in vivo
based on changes in the signal intensity of the neuronal
marker compound, N-acetylaspartate (NAA) [4]. NAA is
synthesized by neuronal mitochondria and is localized
almost exclusively within neurons, including dendrites and
axons. NAA density in the brain can vary due to a change
in the relative partial volume of neurons, such as occurs
with neuroaxonal loss, or to a change in the concentration
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of NAA within neurons, such as occurs with sublethal
neuroaxonal injury. NAA metabolism is linked to mito-
chondrial metabolism, and decreases in NAA may be at
least partially reversible [5]. This is central to the useful-
ness of NAA as a marker of neuroaxonal integrity, since
mitochondrial dysfunction is often an early accompaniment
of injury.
In untreated patients with relapsing-remitting multiple
sclerosis (RRMS), the ratio of NAA to creatine concentra-
tion (NAA/Cr) determined by magnetic resonance spec-
troscopy (MRS) is lower than normal [4], and decreases by
approximately 5 % per year [6, 7]. This decrease in NAA/Cr,
which is dominated by changes in normal-appearing tissue,
correlates with increases in EDSS scores more strongly than
conventional MRI metrics based on focal white matter
lesions [8]. Preliminary data from small studies without
randomization or placebo controls have suggested that
treatment with glatiramer acetate (GA) may be able to slow
or reverse expected declines in NAA/Cr [9–11].
In order to more definitively establish whether GA could
slow or reverse the expected decline in NAA over time in
patients with a clinically isolated syndrome (CIS), we
performed a prospective substudy utilizing MRS in a
subgroup of patients participating in a large phase III,
multicenter, randomized, placebo-controlled trial of GA in
patients with CIS (the PreCISe study [12, 13]).
Methods
PreCISe trial
Details of the design and results of the PreCISe trial have
been presented elsewhere [12] (The trial is registered with
clinicaltrials.gov, number NCT00666224). The protocol
and patient consent documents were approved by the
institutional review boards and ethics committees of the
participating centers. In brief, the trial consisted of a three-
year, randomized, placebo-controlled, double-blind com-
parison of GA 20 mg SC QD and matching placebo in
patients with CIS suggestive of MS. A total of 481 patients
were randomized at 80 centers around the world. The main
inclusion criteria were a single, unifocal clinical attack and
a brain MRI showing two or more lesions at least 6 mm in
diameter. The primary aim of the study was to assess the
efficacy of GA in CIS. Following conversion to clinically
definite MS (CDMS) or after 3 years, whichever came first,
patients could switch to active treatment with GA for a
total treatment duration of 5 years.
The placebo-controlled phase of the trial [12] was ter-
minated early, as a preplanned interim analysis of the
results favored treatment with GA over placebo, and the
data monitoring committee recommended, with sponsor
approval, to offer all patients the opportunity to roll over
into the open-label phase of active GA therapy for 2 years.
MRS substudy
This prospectively planned MRS substudy included 34
patients enrolled at 10 clinical sites in seven countries. All
patients gave informed consent before participating in this
substudy. This study was performed in accordance with the
International Conference on Harmonization good clinical
practice guidelines and the study protocol was reviewed and
approved by the institutional review board or ethics com-
mittee at participating sites. The study was approved by the
institutional review boards of participating centers and was
conducted in accordance with the Declaration of Helsinki.
Water-suppressed proton spectra were obtained prior to
injection of gadolinium (Gd) from a brick-shaped volume of
interest centered on the corpus callosum using a 90–180–
180 (PRESS) sequence (TR 2,000, TE 272, number of
acquisitions 128). A water-unsuppressed reference scan to
enable correction for eddy currents was obtained immediately
after the water-suppressed scan using exactly the same TR,
TE, voxel position and shim settings, but using only 16
acquisitions. The voxel measured 50 mm left–right 9 70 mm
antero-posteriorly 9 18 mm superior-inferiorly and was
rotated around the left–right axis to be parallel to the sub-
callosal line. The voxel was positioned superior-inferiorly so
that the inferior margin of the voxel was at the level of the
angle of the corpus callosum and the fornix on the mid-sagittal
MRI, and antero-posteriorly so that the anterior margin of the
voxel was aligned with the anterior tip of the genu (Fig. 1).
In practice, the so-called NAA peak measured by proton
MRS in human brain originates from the N-acetyl groups
(NA) present primarily in NAA, with a small contribution
from N-acetylaspartylglutamate (NAAG), which also is a
neuroaxonal-specific marker. Thus, although the convention
is to report the peak as ‘NAA’, the total NAA ? NAAG
signal is used rather than the signal from NAA alone, because
NAA and the much-smaller NAAG resonances are not well
resolved at standard field strengths, and the total NAA ?
NAAG signal is more reliably measured. Results are
expressed as the ratio of NAA to total creatine in the VOI.
Quantification of spectra was performed centrally at
NeuroRx Research using LCModel [14] and raw digital
MRS data that were provided by clinical sites.
Results
Baseline characteristics
Baseline characteristics for patients in the main study and the
MRS substudy are shown in Table 1. Nineteen patients were
1902 J Neurol (2013) 260:1901–1906
123
randomized to treatment with GA and 15 to placebo. Pre-
treatment NAA/Cr concentrations in the two groups were the
same. Since patients terminated when they relapsed and
developed CDMS, the numbers of patients available for
follow-up decreased with time over the length of the study.
At 12 months, 11 patients treated with GA and nine patients
who received placebo remained in the MRS substudy.
Primary endpoint of the main study
In the overall PreCISe study, patients treated with GA had
a 45 % reduction in the risk of developing CDMS com-
pared to patients treated with placebo, and the time to the
disease-defining relapse was delayed by approximately 1
year [12].
Results of the MRS substudy
In patients treated with GA (n = 11), NAA/Cr increased by a
mean of 0.14 from baseline to 12 months. In placebo-treated
patients (n = 9), NAA/Cr decreased by 0.33 from baseline to
12 months (Fig. 2). Changes from baseline NAA/Cr differed
significantly between the groups (p = 0.03) at month 12.
Analysis of covariance examining the effect of T2-
weighted lesions, categorized by the presence or absence of
new T2-weighted lesions, showed that increased NAA/Cr
was significant in patients who developed new T2-weighted
lesions over the course of the study. Scans of these patients
were reviewed and it was determined that these new T2-
weighted lesions were not located in the VOI for MRS.
For the relatively small number of patients included in
this MRS substudy, significant differences between GA
treatment and placebo were not found in other MRI out-
come measures (including contrast-enhancing lesion fre-
quency, new T2-weighted lesion counts, T2 lesion volumes
and percent brain volume change) or in EDSS scores.
Discussion
In this phase III, randomized, placebo-controlled trial of
GA therapy for patients with CIS, patients who received
Fig. 1 Voxel placement. Voxel positions were a a sagittal MRI
displaying the single voxel used for MRS angulated parallel to the
callosal line, with the bottom edge of the voxel at the intersection of
the corpus callosum and the fornix, and the anterior edge of the voxel
aligned with the anterior tip of the genu, b the most caudal transverse
image that intersects the voxel, c a slice through the middle of the
voxel, and d the most superior transverse image intersecting the voxel
Table 1 Baseline characteristics of the complete PreCISe cohort, the MRS subcohort, and subjects with 12-month MRS data
Characteristic
mean ± SD
PreCISe study MRS substudy













Age (years) 32 ± 6.9 31 ± 7.0 33 ± 7.5 33 ± 7.1 33 ± 9.0 32 ± 8.1
Sex 159 (65 %) $ 163 (68 %) $ 14 (74 %) $ 12 (80 %) $ 9 (82 %) $ 9 (100 %) $
84 (35 %) # 75 (32 %) # 5 (26 %) # 3 (20 %) # 2 (18 %) # 0 #
EDSS 1.1 ± 1.0 1.0 ± 1.0 1.3 ± 1.2 1.1 ± 1.1 1.3 ± 1.4 1.2 ± 1.1
NAA/Cr levels 3.3 ± 0.4 3.3 ± 0.6 3.3 ± 0.3 3.3 ± 0.7
# Gd? lesions 1.3 ± 2.8 1.6 ± 2.9 1.9 ± 3 0.9 ± 1 1.7 ± 2.2 0.9 ± 1.2
# T2-weighted lesions 33 ± 34 30 ± 26 37 ± 46 24 ± 23 32 ± 27 29 ± 28
T2 lesion volume (ml) 6.4 ± 7.8 5.7 ± 6.0 7.8 ± 11.1 5.2 ± 4.2 5.8 ± 4.3 6.0 ± 4.7
Brain volume (mm3) 1,533 ± 103 1,549 ± 107 1,541 ± 114 1,541 ± 75 1,547 ± 117 1,574 ± 58
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GA showed improvement in brain neuroaxonal integrity
relative to patients treated with placebo, who showed the
decline expected from natural history studies [6, 7].
The increase in NAA concentrations in patients who
were treated with GA is in keeping with a reversal of pre-
existing sublethal neuroaxonal injury and associated
mitochondrial dysfunction. This phenomenon has been
demonstrated experimentally in animals treated with a
mitochondrial toxin [15], and has been observed in humans
with reversible neuronal injury and dysfunction due to
focal inflammatory lesions in MS and mitochondrial
encephalopathy associated with lactic acidosis and strokes
[5]. Reversible neuronal mitochondrial dysfunction also
may underlie the relation between the relative increase in
NAA/Cr and new T2 lesion formation. Mitochondrial
dysfunction in MS is likely related, at least in part, to an
inflammatory environment in the CNS, and patients who
are actively forming new T2 lesions are likely to have a
more inflammatory environment in their brains. The
increased NAA/Cr was not associated with T2 lesion for-
mation within the VOI per se, but rather was related to
lesion formation remote from the VOI for spectroscopy.
The diffuse nature of this inflammation is an important
consideration, as it may be, at least in part, responsible for
the widespread neuroaxonal degeneration that occurs in
MS.
The absence of a detectable effect of GA on the rate of
atrophy in this substudy is not interpretable, as the number
of patients was too small to detect a slowing of atrophy.
The fact that GA did not just slow the expected decline in
NAA, but rather produced an increase in this marker of
neuroaxonal integrity provided the statistical power that
allowed the effect to be observed by MRS, despite the
small number of patients. In addition, acceleration of
atrophy after initiation of anti-inflammatory therapy may
attenuate the sensitivity to detect a true slowing of atrophy
over the first year or two of therapy [16, 17].
This is the first time a treatment effect has been dem-
onstrated in a multicenter, randomized, placebo-controlled
clinical trial using the pathologically specific neuroaxonal
marker, NAA. Similar findings have been reported previ-
ously for RRMS patients treated with GA [9–11], and
inconsistently for patients treated with interferon beta [18,
19], but those data are only from small, single-center
studies that did not use randomization or placebo controls.
Two previous multicenter, randomized, placebo-controlled
trials of GA have acquired MRS data in a subset of
patients. One study [20] evaluated an oral formulation of
GA in patients with relapsing-remitting disease and the
other examined subcutaneous administration of GA in
patients with primary progressive MS [21]. In both of these
trials, the therapy was ineffective on all outcomes,
including changes in NAA levels [22]. This is the first
study to assess the effect of GA on neuroaxonal integrity in
patients with CIS. The difference in findings between the
current study, which showed significant improvement in
NAA levels in GA-treated patients at 12 months, and the
negative outcomes of the GA studies above, may be due to
the fact that patients in the current study received GA at an
early stage of disease, when subclinical axonal injury is
still reversible. Recent observations using magnetic trans-
fer ratio (MTR) as a marker of myelin content suggest that
attenuation of demyelination or improvement of remyeli-
nation by GA may contribute to axonal preservation [23].
Although absolute and semi-absolute quantification of
MRS-measured NAA is often attempted [24], we and
others prefer to normalize the NAA signal intensity to that
of creatine and phosphocreatine (Cr) in the same voxel.
This ratio is straightforward to calculate in the context of
multicenter clinical trials and corrects for many sources of
variability that can affect estimates of absolute NAA con-
centration. For example, because Cr is present in virtually
all types of brain tissue, but is not present in the cerebro-
spinal fluid, NAA/Cr ratios are insensitive to the effects of
edema, brain atrophy, and sulcal enlargement—pathologi-
cal changes that have been shown to be present even in
patients with CIS suggestive of MS [25, 26]. In addition,
changes in the relaxation time of Cr parallel changes in
relaxation times of NAA, which at least partially corrects
for pathological changes in relaxation times [27]. Cor-
recting for all the above factors in absolute quantification is
difficult since it is necessary to determine the volume of
tissue from which the MRS signal originates and to correct
for changes in T1 and T2 relaxation times of each of the
metabolite resonances. Since it is not feasible to measure
these quantities in the context of a clinical trial, absolute or
semi-absolute quantification would require estimates and
assumptions based on healthy subjects or other MS popu-
lations. Such assumptions necessarily contain errors that




























Fig. 2 Change from baseline NAA/Cr. Change from baseline in
NAA/Cr in patients who had not converted to CDMS and were still in
the double-blind phase of the trial at 12 months
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using intravoxel creatine avoids the effect of not knowing
these quantities. Although the concentration of Cr may be
slightly altered in MS, any alteration is likely to be very
small or non-existent in patients with CIS, and are intrin-
sically accounted for in our analysis, since we report dif-
ferences in the ratio of NAA/Cr between groups of subjects
randomized to either GA or placebo [28].
The observations reported here support neuroprotective
activity by GA, and importantly, demonstrate the general
feasibility of using MRS to monitor sublethal neuroaxonal
injury and its potential response to therapy in the context of
multicenter clinical trials.
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